Bioprinted bonoid-on-a-chip model for studying drug effects on human osteocyte differentiation
Biofabrication · 01.09.2026 · 18 (3) · 035030
DOI: 10.1088/1758-5090/ae7ed2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biofabrication, online erschienen am 15.07.2026. Verfasst von Julia Scheinpflug und 9 weiteren Autor:innen. Beteiligte Einrichtung: German Federal Institute for Risk Assessment (BfR), German Centre for the Protection of Laboratory Animals (Bf3R), 10589 Berlin, Germany. Hauptthemen laut MEDLINE: Osteocytes, Cell Differentiation, Bioprinting, Lab-On-A-Chip Devices. Die Arbeit nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Institute for Risk Assessment.
Abstract (Originalsprache)
Osteocytes form an extensive dendritic network within bone tissue that senses mechanical and biochemical stimuli, critical for bone homeostasis. However, the complex interplay between mechanotransduction, oxygen tension, and osteocyte differentiation remains difficult to study due to the lack of physiologically relevant human in vitro models. Previously, we developed a microphysiological system (MPS) that integrates perfusion, mechanical loading, and oxygen control within a culture platform that enables the culture of bone-like three-dimensional (3D) constructs [1]. Here, we demonstrate the application of this MPS as Bonoid-on-a-chip (BoC)-platform to investigate osteoblast-to-early osteocyte transition and mechanosensitive signalling in a human-relevant 3D context, under different physical and chemical conditions. We generated bonoids by bioprinting primary human osteoblasts into a gelatine-hydrogel and cultured them under either static conditions or as dynamic BoC. Different BoC environments consisting in controlled perfusion (0.5 ml min −1 ), mechanical loading (0% or 10% compression, 1 Hz frequency), and physiological oxygen tension (21% or 12%) over a seven-day period were compared. These different models were additionally treated with dexamethasone (DEXA), to evaluate early osteocyte-targeted effects of drug exposure under these different conditions. We observed high cell viability across all conditions, but clear differences in metabolic activity, morphological changes, and mechanotransduction markers between static and dynamic cultures. Notably, cells within the BoC-platform exhibited extended dendritic processes and significantly increased secretion of prostaglandin E2 and nitrite in response to mechanical stimulation - hallmarks of osteocytic signalling in mechanotransduction. When testing the new BoC as platform for early osteocyte-targeted investigations, we found DEXA exposure disrupting this mechanoresponsive phenotype, highlighting the model’s applicability for pharmacological screening. These findings demonstrate the value of our BoC-platform as a human-relevant model for studying bone mechanobiology and drug responses in vitro . This approach offers a promising alternative to animal models in bone research and opens new avenues for investigating osteocyte function under physiologically dynamic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- German Federal Institute for Risk Assessment (BfR), German Centre for the Protection of Laboratory Animals (Bf3R), 10589 Berlin, Germany.
- Cellbricks GmbH, 13353 Berlin, Germany.
- Technische Universität Berlin, 13355 Berlin, Germany.
- DRK Kliniken Westend, 14050 Berlin, Germany.
- Institute of Veterinary Physiology, Faculty of Veterinary Medicine, University of Leipzig, 04103 Leipzig, Germany.
- Institute of Clinical Pharmacology and Toxicology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
ORCID-Profile: Julia Scheinpflug, Chris Tina Höfer, Matthias Steinfath, Alexander Thomas, Sarah S Schmerbeck, Thilo John, Marlon R Schneider, Gilbert Schönfelder, Frank Schulze, Marta Barenys
Förderung
- German Federal Institute for Risk Assessment
Zitieren
APA
Scheinpflug, J., Höfer, C. T., Steinfath, M., Thomas, A., Schmerbeck, S. S., John, T., Schneider, M. R., Schönfelder, G., Schulze, F., & Barenys, M. (2026). Bioprinted bonoid-on-a-chip model for studying drug effects on human osteocyte differentiation. Biofabrication, 18(3), 035030. https://doi.org/10.1088/1758-5090/ae7ed2
Vancouver
Scheinpflug J, Höfer CT, Steinfath M, Thomas A, Schmerbeck SS, John T, et al. Bioprinted bonoid-on-a-chip model for studying drug effects on human osteocyte differentiation. Biofabrication. 2026;18(3):035030. doi:10.1088/1758-5090/ae7ed2
BibTeX
@article{Scheinpflug2026,
author = {Scheinpflug, Julia and Höfer, Chris Tina and Steinfath, Matthias and Thomas, Alexander and Schmerbeck, Sarah S and John, Thilo and Schneider, Marlon R and Schönfelder, Gilbert and Schulze, Frank and Barenys, Marta},
title = {Bioprinted bonoid-on-a-chip model for studying drug effects on human osteocyte differentiation},
journal = {Biofabrication},
year = {2026},
volume = {18},
number = {3},
pages = {035030},
doi = {10.1088/1758-5090/ae7ed2}
}
EUVIMED